NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

NCT04155541

CompletedN/A

Sponsor: Pfizer

Conditions: EGFR Mutation-positive Inoperable or Reccrent NSCLC

Interventions: dacomitinib hydrate

Countries: Japan

Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice

Eligibility overview

Sex: ALL

Age: 0 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* patient with EGFR mutation-positive inoprable or recurrent NSCLC who have not received VIZIMPRO(dacomitinib hydrate)

Exclusion Criteria:

* Exclusion criteria is not provided in this study

Locations (1)

Tokyo, Japan